An open call for influenza vaccination pending the new wave of COVID‐19

Özaras, Reşat; Cirpin, Rasim; Duman, Habibe; Duran, Arif; Arslan, Özgür; Leblebicioğlu, Hakan

doi:10.1002/jmv.26272

Cited by 12 publications

(21 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In previous studies, the frequency and clinical outcomes of co‐infection with influenza virus were variable 16,17 . Co‐infection was uncommon in Northern California, United States (0.9%), 18 and Turkey (0.54%) 19 .…”

Section: Discussionmentioning

confidence: 97%

“…CT, computed tomography; IFV, influenza A virus; IgM, immunoglobulin M; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2The CT features, including the location, extent and distribution of each abnormality are presented in Table3. The median time from onset of symptoms to CT scan were 18 (12-23) days for patients with SARS-CoV-2 infection only and 20(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27) days for patients with co-infection (p = .487). Four patients (two with SARS-CoV-2 infection only and two with co-infection) had normal CT scan.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Co‐infection of influenza A virus and SARS‐CoV‐2: A retrospective cohort study

Cheng

Wang

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

The coronavirus 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread across the world and is responsible for over 1,686,267 deaths worldwide. Co-infection with influenza A virus (IFV-A) during the upcoming flu season may complicate diagnosis and treatment of COVID-19. Little is known about epidemiology and outcomes of co-infection. Data for 213 COVID-19 patients treated at Tongji Hospital in Wuhan from January 28, 2020 to March 24, 2020 were retrospectively analyzed. Ninety-seven of the patients (45.5%) tested positive for anti-IFV-A immunoglobulin M antibodies. The clinical characteristics were described and analyzed for patients with SARS-CoV-2 infection only and patients with SARS-CoV-2/IFV-A co-infection. Patients with co-infection showed similar patterns of symptoms and clinical outcomes to patients with SARS-CoV-2 infection only. However, an increased expression of serum cytokines (interleukin-2R [IL-2R], IL-6, IL-8, and tumor necrosis factor-α) and cardiac troponin I, and higher incidence of lymphadenopathy were observed in patients with SARS-CoV-2 infection only. Male patients and patients aged less than 60 years in the SARS-CoV-2 infection group also had significantly higher computed tomography scores than patients in co-infection group, indicating that co-infection with IFV-A had no effect on the disease outcome but alleviated inflammation in certain populations of COVID-19 patients. The study will provide a reference for diagnosing and treating IFV-A and SARS-CoV-2 co-infection cases in the upcoming flu season.

show abstract

Section: Discussionmentioning

confidence: 97%

mentioning

confidence: 99%

Co‐infection of influenza A virus and SARS‐CoV‐2: A retrospective cohort study

Cheng

Wang

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…To date, this disease has spread in many countries and has resulted in millions of cases of infection and thousands of deaths all over the world. 7 Recently published reports of concurrent infections of other respiratory viruses such as influenza virus [8][9][10][11][12] and human metapneumovirus 13,14 with SARS-CoV-2 infection have suggested that coinfection could affect the morbidity and mortality ratio. In addition to these, due to the wide range of symptoms in patients and relatively higher mortality in comparison with the global rate, 15 in Iran.…”

Section: Discussionmentioning

confidence: 99%

High prevalence of SARS‐CoV‐2 and influenza A virus (H1N1) coinfection in dead patients in Northeastern Iran

Hashemi

Safamanesh

Ghasemzadeh‐Moghaddam

et al. 2020

Journal of Medical Virology

105

115

View full text Add to dashboard Cite

In the last months of 2019, an outbreak of fatal respiratory disease started in Wuhan, China, and quickly spread to other parts of the world. It was named COVID-19, and to date, thousands of cases of infection and death are reported worldwide. This disease is associated with a wide range of symptoms, which makes accurate diagnosis of it difficult. During previous severe acute respiratory syndrome (SARS) pandemic in 2003, researchers found that the patients with fever, cough, or sore throat had a 5% influenza virus-positive rate. This finding made us think that the wide range of symptoms and also relatively high prevalence of death in our patients may be due to the coinfection with other viruses. Thus, we evaluated the coinfection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with other re

show abstract

“…As the bulk of the second wave of COVID-19 approaches, there is the additional worry of influenza season. Although there is evidence demonstrating that measures used to control the spread of COVID-19 decreases influenza activity substantially, there are still reports of co-infection [ 17 – 19 ]. This co-infection has the potential to complicate prognosis and is especially concerning in high-risk groups such as older individuals, those with chronic diseases and the immunocompromised [ 20 , 21 ].…”

Section: Discussionmentioning

confidence: 99%

Pharmacy response to COVID-19: lessons learnt from Canada

Elbeddini

Botross

Gerochi

et al. 2020

J of Pharm Policy and Pract

View full text Add to dashboard Cite

When the first wave of COVID-19 hit in March 2020, health care professionals across Canada were challenged to quickly and efficiently adapt to change their work practices in these unprecedented times. Pharmacy professionals, being some of the very few front-line health care workers who remained accessible in person for patients, had to rapidly adopt critical changes in their pharmacies to respond in the best interest of their patients and their pharmacy staff. As challenging and demanding as such changes were, they provided pharmacists with invaluable lessons that would be imperative as the country enters a potentially more dangerous second wave. This article seeks to identify and summarize opportunities for improvement in pharmacy as learnt from the pandemic’s first wave. Such areas include but are not limited to handling of drug shortage and addressing drug hoarding and stockpiling, providing physical and mental support for staff, timing of flu vaccine and COVID-19 screening/testing, collaboration between different health care sites as well as collaboration with patients and with other health care professionals, telemedicine and willingness to adopt innovative ideas, need for more staff training and more precise research to provide accurate information and finally the need for more organizational and workplace support. Learning from what went well and what did not work in the early stages of the pandemic is integral to ensure pharmacy professionals are better prepared to protect themselves and their patients amidst a second and possibly subsequent waves.

show abstract

An open call for influenza vaccination pending the new wave of COVID‐19

Abstract: We have read the study of Yue et al 1 with great interest. They reported influenza coinfection among 307 coronavirus disease 2019 (COVID-19) patients as 57.3%. The study included a period

Cited by 12 publications

References 13 publications

Co‐infection of influenza A virus and SARS‐CoV‐2: A retrospective cohort study

Co‐infection of influenza A virus and SARS‐CoV‐2: A retrospective cohort study

High prevalence of SARS‐CoV‐2 and influenza A virus (H1N1) coinfection in dead patients in Northeastern Iran

Pharmacy response to COVID-19: lessons learnt from Canada

Contact Info

Product

Resources

About